Satya Kalyan Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Ebitda
- Net Worth
- Total Assets 0.96%
(FY 2023)
About Satya Kalyan Pharmaceuticals
The Corporate was formerly known as Satya Kalyan Estates & Infrastructures Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Murali Vankayalapati, Rajarajeswari Vankayalapati, and Kalyan Vankayalapati serve as directors at the Company.
- CIN/LLPIN
U74110AP2014PTC095129
- Company No.
095129
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Aug 2014
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Satya Kalyan Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Murali Vankayalapati  | Director | 22-Aug-2014 | Current |
| Rajarajeswari Vankayalapati | Director | 22-Aug-2014 | Current |
| Kalyan Vankayalapati | Director | 22-Aug-2014 | Current |
Financial Performance of Satya Kalyan Pharmaceuticals.
Satya Kalyan Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Satya Kalyan Pharmaceuticals?
In 2023, Satya Kalyan Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
V.K.Ferro Alloys Pvt.Ltd.Active 47 years 17 daysMurali Vankayalapati, Rajarajeswari Vankayalapati and 1 more are mutual person
- Satya Kalyan Constructions Private LimitedActive 29 years 7 months
Murali Vankayalapati, Rajarajeswari Vankayalapati and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Satya Kalyan Pharmaceuticals?
Unlock and access historical data on people associated with Satya Kalyan Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Satya Kalyan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Satya Kalyan Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
